Merck and Gilead's Combined HIV Drug Meets Primary Goals in Late-Stage Trials

Inovio Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Quest Diagnostics Inc. Stock Underperforms Monday When Compared To Competitors

Merck, Gilead Discontinue Phase 3 Trial of Trodelvy, Keytruda to Treat Lung Cancer

BRIEF-Merck And Gilead Provide Update On Phase 3 Keynote-D46/Evoke-03 Study

Merck, Gilead announce discontinuation of Phase 3 KEYNOTE-D46/EVOKE-03 study

Gilead, Merck say once-weekly HIV pill meets Phase 3 endpoint in ISLEND trials

Gilead: Co, Merck Plan to File Phase 3 Data From Islend Trials of Islatravir/Lenacapavir With Regulatory Authorities Globally

Gilead: Announces Positive Topline Results From Two Phase 3 Studies Evaluating Oral Once-Weekly Hiv Treatment Islatravir and Lenacapavir

Gilead: No New Safety Concerns Were Identified in Both Trials With Islatravir/Lenacapavir

Quest Diagnostics SVP Clinical Solutions Karthik Kuppusamy disposes of shares worth $1,629,400

Merck, Gilead halt Phase 3 KEYNOTE-D46/EVOKE-03 lung cancer trial after PFS misses significance

Gilead: Discontinuation of Phase 3 Keynote-D46/Evoke-03 Study Investigating Gilead's Trodelvy in Combination With Keytruda

Gilead: Safety Profile of Trodelvy in Combination With Keytruda Consistent With Known Safety of Each Agent

Gilead: Study Did Not Achieve Statistical Significance for Progression-Free or Overall Survival

Gilead: No Changes to Ongoing Trodelvy or Merck Studies

Noveris Health Sciences appoints Geoff Griffiths as strategic advisor

Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says

Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Hinge Health, Inc. Class A (HNGE) and MoonLake Immunotherapeutics (MLTX)